Sosei : Investor Webinar Q&A - Collaboration with Neurocrine Biosciences to Develop Novel Muscarinic Receptor Agonists

NON - CONFIDENTIAL

Collaboration with Neurocrine Biosciences to Develop Novel Muscarinic Receptor Agonists

For Schizophrenia and Other Neuropsychiatric Disorders

2021 | © Sosei Group Corporation

Disclaimer

The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the "Company") as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice to recipients. It is not targeted to the specific investment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third party evaluation of any securities or any offering of them and should not be considered as a recommendation that any recipient should subscribe for or purchase any securities.

The information contained herein is in summary form and does not purport to be complete. Certain information has been obtained from public sources. No representation or warranty, either express or implied, by the Company is made as to the accuracy, fairness, or completeness of the information presented herein and no reliance should be placed on the accuracy, fairness, or completeness of such information. The Company takes no responsibility or liability to update the contents of this presentation in the light of new information and/or future events. In addition, the Company may alter, modify or otherwise change in any manner the contents of this presentation, in its own discretion without the obligation to notify any person of such revision or changes.

This presentation contains "forward-looking statements," as that term is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. The words "believe", "expect", "anticipate", "intend", "plan", "seeks", "estimates", "will" and "may" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. These factors include, without limitation, those discussed in our public reports filed with the Tokyo Stock Exchange and the Financial Services Agency of Japan. Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonably based on information currently available to the Company's management, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation and the company does not assume any obligations to update or revise any of these forward statements, even if new information becomes available in the future.

This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Recipients of this presentation are not to construe the contents of this summary as legal, tax or investment advice and recipients should consult their own advisors in this regard.

This presentation and its contents are proprietary confidential information and may not be reproduced, published or otherwise disseminated in whole or in part without the Company's prior written consent. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

This presentation contains non-GAAP financial measures. The non‐GAAP financial measures contained in this presentation are not measures of financial performance calculated in accordance with IFRS and should not be considered as replacements or alternatives profit, or operating profit, as an indicator of operating performance or as replacements or alternatives to cash flow provided by operating activities or as a measure of liquidity (in each case, as determined in accordance with IFRS). Non-GAAP financial measures should be viewed in addition to, and not as a substitute for, analysis of the Company's results reported in accordance with IFRS.

References to "FY" in this presentation for periods prior to 1 January 2018 are to the 12-month periods commencing in each case on April 1 of the year indicated and ending on March 31 of the following year, and the 9 month period from April 1 2017 to December 31 2017. From January 1 2018 the Company changed its fiscal year to the 12-month period commencing in each case on January 1. References to "FY" in this presentation should be construed accordingly.

© Sosei Group Corporation. Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation. Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

2

Today we are joined by Dr. Eiry Roberts, CMO at Neurocrine

DR. EIRY ROBERTS

CHIEF MEDICAL OFFICER

• Appointed Chief Medical Officer in January 2018 and is responsible for all clinical development and medical affairs activities at Neurocrine.
• Over 25 years of research and development experience in the pharmaceutical industry across all phases of drug development from research through commercialization in multiple therapeutic areas, including neuroscience, inflammation, oncology and metabolic diseases.
• Joined Neurocrine from Eli Lilly and Company where she had worked since May 1991, holding various positions of increasing responsibility, including Vice President, Clinical Pharmacology/Managing Director of Chorus (October 2014 to December 2017) and Vice President of R&D, BioMedicines Business Unit.
• Trained physician in pharmacology and medicine in the UK, qualifying from the University of London in 1987. Her post-graduate clinical training was in clinical pharmacology and cardiology at St. Bartholomew's Hospital and the Royal London Hospital.
• Also serves as a director of Amicus Therapeutics, a clinical-stage biopharmaceutical company focused on rare diseases.

3

Announcing our up to US$2.7 billion collaboration with Neurocrine

Developing novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric disorders

1

2

3

4

Neurocrine gains rights to a portfolio of potential best-in-class selective muscarinic receptor agonists in development for the treatment of major CNS disorders

Sosei Heptares receives US$100 million upfront which will likely be recognized as Revenue in FY2021

Sosei Heptares to receive ongoing R&D funding and up to US$1.5 billion in potential development and regulatory milestones, up to US$1.1 billion in commercial milestones, plus tiered up to mid-teenpercentage royalties on net sales

Sosei Heptares also retains the rights to develop all muscarinic M1 agonists in

Japan in all indications, with Neurocrine receiving co-development and profit share options

Licensed Portfolio

M4 agonists

(Global)

Dual M4/M1 agonists

(Global)

M1 agonists

(ex-Japan)

Latest major strategic partnership executed by Sosei Heptares

4

Neurocrine is a leading neuroscience-focused biopharmaceutical

company…

• Incorporated in 1992, IPO in 1996 (Nasdaq:NBIX), with current market capitalization of ~US$10bn
• First product approved in 2017 - INGREZZA® (valbenazine) indicated for Tardive Dyskinesia
• Focused on discovery and development of novel therapeutics for CNS and endocrine diseases
• Headquartered in San Diego, California with approximately 900 employees

Global and Regional Partnerships

Flagship Japan-based partners of Neurocrine

• Exclusive collaboration and licensing agreement to develop and commercialize valbenazine (INGREZZA®) for movement disorders in Japan and other select Asian markets
• NBIX retained full commercial rights in North America, Europe and other countries outside of Asia

March 2015

• Strategic collaboration to develop and commercialize compounds in Takeda's early-to-mid stage psychiatry pipeline
• NBIX received exclusive license for seven Takeda pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia

June 2020

Strong history of partnering with Japan's leading science-led major pharmaceutical companies

5